Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
JPMorgan: The U.S. stock market “Magnificent Seven” and the storage sector are expected to continue rising.

JPMorgan: The U.S. stock market “Magnificent Seven” and the storage sector are expected to continue rising.

格隆汇格隆汇2026/06/02 03:47
Show original
格隆汇 June 2|On Monday Eastern Time, JPMorgan maintained its optimistic view on the U.S. stock "Magnificent Seven" in a report to clients, stating that after a correction earlier this year, the "Magnificent Seven" still have room for further price increases. JPMorgan analyst Mislav Matejka said that since late March this year, JPMorgan has been advising clients to buy stocks during market downturns and remains bullish on the future performance of the "Magnificent Seven". At the end of March this year, the U.S. stock market suffered a collective decline as the Iran war caused international oil prices to surge, with the "Magnificent Seven" falling to stage lows. However, since then, the "Magnificent Seven" have generally rebounded, with Apple, Google, Amazon, and NVIDIA shares hitting new all-time highs once again. Although underlying risks in the Middle East still need attention, JPMorgan believes that the earnings of the "Magnificent Seven" are sufficient to support the price rebound, and noted that the valuations of the "Magnificent Seven" fell to the lowest point in the past ten years in March, creating significant room for a rebound. In addition to the "Magnificent Seven," JPMorgan also pointed out that the storage sector in emerging markets is another field with sustained upward momentum, noting that "before early 2028, the storage market is not expected to see large-scale supply increases." In a previous report, JPMorgan noted that driven by structural AI demand, the global storage chip industry is experiencing the strongest and longest-lasting upward cycle in its history, and the valuation of top memory manufacturers is seeing unprecedented growth.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data

On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)

路透社•2026/10/08 18:26